ORCID: https://orcid.org/0009-0001-2436-8630; Walter, Julia
ORCID: https://orcid.org/0000-0003-4304-6159; Daisenberger, Lea; Kuhnle, Felix; Ingenerf, Maria Katharina
ORCID: https://orcid.org/0000-0001-6465-4597; Schmid-Tannwald, Christine; Brendel, Matthias
ORCID: https://orcid.org/0000-0002-9247-2843; Kauffmann-Guerrero, Diego
ORCID: https://orcid.org/0000-0003-1471-3290; Heinzerling, Lucie
ORCID: https://orcid.org/0000-0001-5718-3643; Tufman, Amanda; Pfluger, Thomas und Völter, Friederike
ORCID: https://orcid.org/0000-0001-6157-0363
(2024):
The Association between the Body Mass Index, Chronic Obstructive Pulmonary Disease and SUV of the Non-Tumorous Lung in the Pretreatment [18F]FDG-PET/CT of Patients with Lung Cancer.
In: Diagnostics, Bd. 14, Nr. 11, 1139
[PDF, 3MB]

Abstract
Background: A debate persists on the prognostic value of the pre-therapeutic standardized uptake value (SUV) of non-tumorous lung tissue for the risk assessment of therapy-related pneumonitis, with most studies lacking significant correlation. However, the influence of patient comorbidities on the pre-therapeutic lung SUV has not yet been systematically evaluated. Thus, we aimed to elucidate the association between comorbidities, biological variables and lung SUVs in pre-therapeutic [18F]FDG-PET/CT. Methods: In this retrospective study, the pre-therapeutic SUV in [18F]FDG-PET/CT was measured in non-tumorous areas of both lobes of the lung. SUVMEAN, SUVMAX and SUV95 were compared to a multitude of patient characteristics and comorbidities with Spearman’s correlation analysis, followed by a Bonferroni correction and multilinear regression. Results: In total, 240 patients with lung cancer were analyzed. An elevated BMI was significantly associated with increased SUVMAX (β = 0.037, p < 0.001), SUVMEAN (β = 0.017, p < 0.001) and SUV95 (β = 0.028, p < 0.001). Patients with chronic obstructive pulmonary disease (COPD) showed a significantly decreased SUVMAX (β = −0.156, p = 0.001), SUVMEAN (β = −0.107, p < 0.001) and SUV95 (β = −0.134, p < 0.001). Multiple other comorbidities did not show a significant correlation with the SUV of the non-tumorous lung. Conclusions: Failure to consider the influence of BMI and COPD on the pre-therapeutic SUV measurements may lead to an erroneous interpretation of the pre-therapeutic SUV and subsequent treatment decisions in patients with lung cancer.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin > Munich Cluster for Systems Neurology (SyNergy)
Medizin > Institut für Schlaganfall- und Demenzforschung (ISD) Medizin > Klinikum der LMU München > Klinik und Poliklinik für Dermatologie und Allergologie Medizin > Klinikum der LMU München > Medizinische Klinik und Poliklinik III (Onkologie) Medizin > Klinikum der LMU München > Medizinische Klinik und Poliklinik V (Pneumologie) Medizin > Klinikum der LMU München > Klinik und Poliklinik für Nuklearmedizin Medizin > Klinikum der LMU München > Klinik und Poliklinik für Radiologie |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
URN: | urn:nbn:de:bvb:19-epub-122917-2 |
ISSN: | 2075-4418 |
Sprache: | Englisch |
Dokumenten ID: | 122917 |
Datum der Veröffentlichung auf Open Access LMU: | 06. Dez. 2024 12:30 |
Letzte Änderungen: | 06. Dez. 2024 12:30 |
DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198 |